万春医药 BYSI 深 沪
等待开盘 10-14 09:30:00 美东时间
0.6067
-0.009
-1.43%
华盛通- 最 高0.6445
- 今 开0.62
- 成交量 5.34万股
- 最 低 0.6011
- 昨 收 0.6155
- 总市值 2.49万
- 52周最高 2.44
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 0.5657
- 委 比 90.65%
- 总股本 4.11万
- 历史最高 48.49
- 量 比 0.71
- 振 幅 7.05%
- 历史最低 0.542
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BeyondSpring Divests China Assets, Refocuses on Data Partnerships
Beyondspring ( ($BYSI) ) has provided an announcement. On September 30, 2026, B...
10-07 05:02
BeyondSpring Faces Nasdaq Listing Compliance Risk
Beyondspring ( ($BYSI) ) has shared an announcement. On September 29, 2026, Bey...
10-03 05:03
BeyondSpring launches ATM program to bolster financing
Beyondspring ( ($BYSI) ) just unveiled an update. On September 28 and 29, 2026,...
09-29 19:29
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics appoints Rich Daly, a seasoned life sciences executive with over 30 years of experience, to its Board of Directors. Daly's expertise in commercial launches and biopharmaceutical organizations, including roles at AstraZeneca, Takeda, and Catalyst, will support Aquestive's preparation for the potential launch of Anaphylm. The Board now consists of eight directors, seven of whom are independent. Daly's leadership is expected t...
09-29 11:00
BeyondSpring GAAP EPS of -$0.02
BeyondSpring press release (BYSI): Q2 GAAP EPS of -$0.02. Net loss was $1.8 million for the quarter ended June 30, 2026, compared to $1.9 million for the quarter ended June 30, 2025. Cash, cash equiva...
08-17 16:32
BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.
08-15 05:21
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY26 revenue guidance above estimates. Eton Pharmaceuticals reported quarterly earnings of 43 cents per share which beat the...
08-14 16:37
BeyondSpring Appoints Min Qiu As CEO, Effective July 1
Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully
06-04 19:10
Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembrolizumab Plus Plinabulin And Docetaxel In Patients With Metastatic Non-Small Cell Lung Cancer; Sees Meaningful Clinical Benefit
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit:
06-02 19:15
